

FMHL/SE/FEB'24

February 5, 2024

BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
Scrip Code: 523696

Subject: Outcome of the Board Meeting.

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. February 5, 2024, *inter-alia*, considered and approved unaudited standalone and consolidated financial results of the Company for the quarter and period ended December 31, 2023 (“**Quarterly Results**”).

Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for the quarter and period ended on December 31, 2023.

The Board Meeting commenced at 1215 Hours and concluded at 1750 Hours

This is for your information and record please.

Thanking You
For **Fortis Malar Hospitals Limited**



Sandeep Singh
Company Secretary & Compliance Officer
Membership No.: F9877

Encl.: as above

FORTIS MALAR HOSPITALS LIMITED

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062
Tel: +91 172 5096001 Fax: +91 172 5096002 CIN: L85110PB1989PLC045948

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31-DECEMBER-2023

(Rs. in lakhs except equity share data)

No.	Particulars	Standalone Quarter ended			Standalone Nine months ended		Standalone Year ended	Consolidated Quarter ended			Consolidated Nine Months ended		Consolidated Year ended
		31-Dec-2023	30-Sept-2023	31-Dec-2022	31-Dec-2023	31-Dec-2022	31-Mar-2023	31-Dec-2023	30-Sept-2023	31-Dec-2022	31-Dec-2023	31-Dec-2022	31-Mar-2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income												
	a) Revenue from operations	1,758.09	1,814.91	2,190.28	5,349.07	6,529.45	8,595.08	1,758.09	1,814.91	2,190.28	5,349.07	6,529.45	8,595.08
	b) Other income	124.23	229.21	150.52	512.53	461.57	655.78	126.30	231.26	152.28	518.66	466.52	663.81
	Total income	1,882.32	2,044.12	2,340.80	5,861.60	6,991.02	9,250.86	1,884.39	2,046.17	2,342.56	5,867.73	6,995.97	9,258.89
2	Expenses												
	a) Purchase of medical consumables and drugs	298.41	232.15	291.64	774.32	911.00	1,190.47	298.41	232.15	291.64	774.32	911.00	1,190.47
	b) Changes in inventories of medical consumables and drugs	(4.32)	2.19	14.78	(13.25)	78.26	76.02	(4.32)	2.19	14.78	(13.25)	78.26	76.02
	c) Employee benefits expense	441.55	428.56	487.13	1,356.62	1,439.47	1,933.27	443.44	430.45	488.93	1,362.29	1,444.87	1,940.57
	d) Finance costs	126.00	129.99	148.80	390.98	464.75	607.06	126.00	129.99	148.80	390.98	464.75	607.06
	e) Professional charges / consultation fees to doctors	532.69	555.51	650.87	1,631.53	1,886.88	2,487.25	530.52	553.33	648.80	1,625.01	1,880.67	2,478.97
	f) Clinical establishment fees	133.05	135.83	163.65	401.60	491.87	643.61	133.05	135.83	163.65	401.60	491.87	643.61
	g) Depreciation and amortization expenses	290.90	271.58	277.74	829.66	870.23	1,214.66	290.90	271.58	277.74	829.66	870.23	1,214.66
	h) Other expenses	465.13	469.05	422.69	1,366.00	1,336.94	1,806.27	465.97	469.52	423.07	1,368.01	1,338.23	1,808.32
	Total expenses	2,283.41	2,224.86	2,457.30	6,737.46	7,479.40	9,958.61	2,283.97	2,225.04	2,457.41	6,738.62	7,479.88	9,959.68
3	Loss before tax (1-2)	(401.09)	(180.74)	(116.50)	(875.86)	(488.38)	(707.75)	(399.58)	(178.87)	(114.85)	(870.89)	(483.91)	(700.79)
4	Tax expense	-	-	-	-	364.42	845.57	0.72	0.47	0.41	1.59	365.54	847.32
	- Current tax	-	-	-	-	-	-	0.73	0.49	0.42	1.62	1.15	1.81
	- Deferred tax charged/ (credit)	-	-	-	-	364.42	845.57	(0.01)	(0.02)	(0.01)	(0.03)	364.39	845.51
5	Loss after tax (3-4)	(401.09)	(180.74)	(116.50)	(875.86)	(852.80)	(1,553.32)	(400.30)	(179.34)	(115.26)	(872.48)	(849.45)	(1,548.11)
	Other comprehensive income / (loss) (net of tax)												
	Items that will not be reclassified subsequently to the statement of profit and loss:												
	(a) Remeasurements of defined benefit liability	0.05	(2.97)	(8.23)	(12.56)	19.12	(47.94)	0.05	(2.97)	(8.23)	(12.56)	19.12	(47.75)
	(b) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	(0.05)
6	Other comprehensive income / (loss) (net of tax)	0.05	(2.97)	(8.23)	(12.56)	19.12	(47.94)	0.05	(2.97)	(8.23)	(12.56)	19.12	(47.80)
7	Total comprehensive loss for the period / year (5+6)	(401.04)	(183.71)	(124.73)	(888.42)	(833.68)	(1,601.26)	(400.25)	(182.31)	(123.49)	(885.04)	(830.33)	(1,595.91)
	Total comprehensive loss attributable to:												
	- Owners of the company	NA	NA	NA	NA	NA	NA	(400.25)	(182.31)	(123.49)	(885.04)	(830.33)	(1,595.91)
	- Non-controlling interests	NA	NA	NA	NA	NA	NA	-	-	-	-	-	-
8	Paid up equity share capital (face value Rs.10 each)	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70
9	Reserves excluding revaluation reserves - other equity	NA	NA	NA	NA	NA	4,320.04	NA	NA	NA	NA	NA	4,541.54
10	Earnings Per Share (EPS) based on (5) above (of Rs. 10 each) - (Not annualised in the quarters and nine months ended)												
	- Basic	(2.14)	(0.96)	(0.62)	(4.67)	(4.55)	(8.29)	(2.14)	(0.96)	(0.61)	(4.66)	(4.53)	(8.26)
	- Diluted	(2.14)	(0.96)	(0.62)	(4.67)	(4.55)	(8.29)	(2.14)	(0.96)	(0.61)	(4.66)	(4.53)	(8.26)

FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali-160062

Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002

Website: www.fortismalar.com; Email: secretarial.malar@malarhospitals.in

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31-DECEMBER-2023

Notes:

- 1 The unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2023 has been reviewed by the Audit and Risk Management Committee and subsequently approved by the Board of Directors at their respective meeting held on 5 February 2024. The above results have been subjected to limited review by the Statutory auditors of the Company. The auditors have issued an unmodified review report.
- 2 These unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The consolidated financial results includes the financial results of the Company Fortis Malar Hospitals Limited and the financial results of its subsidiary company Malar Stars Medicare Limited (collectively known as "Group").
- 4 The Company is engaged in the Healthcare Services, which in the context of Indian Accounting Standard (Ind AS) 108 - Operating Segments is considered as the only reportable segment of the Company.
- 5 The Company operated its healthcare business from Fortis Malar Hospital situated at Adyar Chennai ("Malar Hospital/ undertaking"). It had "Hospital and Medical Services Agreement" ("HMSA") with Fortis Health Management Limited ("FHML") w.r.t. rendering of certain medical and healthcare services in the hospital premises (including right to use of the hospital building). The hospital building owned by FHML has certain ongoing litigations and issues pertaining to regularisation. Certain clearances and certificates were sought by the authorities in connection with the regularisation and the issues related to the hospital building. FHML and the Company have continuously been taking bonafide steps to get the required clearances/ certificates, regularization of the hospital building and issues related thereto. However, above referred legacy issues gave rise to certain challenges for the Company and constrained further investments into the facility. The circumstances accentuated the need to divest the undertaking as a viable and prudent option in the interest of stakeholders. Accordingly, during the quarter ended 31 December 2023, the Company has entered into Business Transfer Agreement ("BTA") with MGM Healthcare Private Limited ("MGM") for the sale of its business operations pertaining to Malar Hospital, as a going concern, on a slump sale basis, for a sale consideration of approx. Rs 45.50 crores, subject to adjustments and on such terms and conditions (including necessary approvals from the shareholders of the Company and of the holding company, i.e. Fortis Healthcare Limited) as contained in BTA ("slump sale transaction"). The transaction is an all-cash deal. Upon closing and with effect only from closing date, the undertaking along with all related assets and liabilities shall stand transferred and vested in MGM. Further, the HMSA with FHML will get automatically terminated post this transaction and the above building regularisation related matter will not be expected to have any impact on the Company in future. Subsequent to quarter ended 31 December 2023, based on approval of the shareholders of the Company and the holding company (received on 03 January 2024 and 01 January 2024 respectively), the transaction was consummated on 1 February 2024. Accordingly, the Company is no longer associated with the hospital building and related uncertainties such as pending regularisation and ongoing litigations related thereto. Since, the criteria for classifying the assets as held for sale/discontinuing operations or for giving effect to the BTA has not been met as at 31 December 2023, the Company has not classified the undertaking as held for sale/discontinuing operations or given effect to the BTA in these financial results. Post the BTA, the Company ceases to have any business operations. The Company has sufficient cash and cash equivalent balance to settle its obligations as and when they fall due and the Company believes that it would be able to meet its financial requirements and accordingly these financial results have been prepared on a going concern basis. The Company will evaluate in due course the utilization of its resources in the best interest of shareholders (including distribution of dividend, in compliance with applicable laws and regulations).
- 6 Figures for the prior periods / year have been reclassified/ regrouped wherever required to conform to the classification of the current periods / year.
- 7 These financial results are available on the BSE website (www.bseindia.com) and on the Company's website (www.fortismalar.com).

By Order of the Board
Fortis Malar Hospitals Limited
CIN: L85110PB1989PLC045948

CHANDRASEKA Digitally signed by
R RAMASWAMY CHANDRASEKAR RAMASWAMY
Chandrasekar R Date: 2024.02.05 17:34:35
+05'30'

Whole Time Director
DIN : 09414564

Place : Chennai
Date: 05 February 2024

Limited Review Report on unaudited standalone financial results of Fortis Malar Hospitals Limited for the quarter ended 31 December 2023 and year to date results for the period from 01 April 2023 to 31 December 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**To the Board of Directors of Fortis Malar Hospitals Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Fortis Malar Hospitals Limited (hereinafter referred to as “the Company”) for the quarter ended 31 December 2023 and year to date results for the period from 01 April 2023 to 31 December 2023 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to Note 5 to the standalone financial results which describes the litigations and issues pertaining to regularization of the hospital building in which the Company operates as at 31 December 2023 and the subsequent Business Transfer Arrangement (“BTA”) entered into by the Company and related matters.

Subsequent to entering into the BTA, the Company is no longer associated with the hospital building and related uncertainties such as pending regularization and ongoing litigations related thereto.

Further, post the BTA the Company ceases to have any business operations and will evaluate in due course the utilization of its resources. However, the Company believes that it has sufficient cash and cash equivalent to settle its obligations as and when they fall due, and it believes that it would be able to meet its financial requirements and have accordingly prepared the financial results on a going concern basis.

Our conclusion is not modified in respect of this matter.

Registered Office:

Limited Review Report (Continued)

Fortis Malar Hospitals Limited

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

**HARSH VARDHAN
LAKHOTIA**

Digitally signed by HARSH
VARDHAN LAKHOTIA

Date: 2024.02.05 17:48:13
+05'30'

Harsh Vardhan Lakhotia

Partner

Chennai

05 February 2024

Membership No.: 222432

UDIN:24222432BKGUDB7402

Limited Review Report on unaudited consolidated financial results of Fortis Malar Hospitals Limited for the quarter ended 31 December 2023 and year to date results for the period from 01 April 2023 to 31 December 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**To the Board of Directors of Fortis Malar Hospitals Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Fortis Malar Hospitals Limited (hereinafter referred to as “the Parent”), and its subsidiary (the Parent and its subsidiary together referred to as “the Group”) for the quarter ended 31 December 2023 and year to date results for the period from 01 April 2023 to 31 December 2023 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the subsidiary company, Malar Stars Medicare Limited.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We draw attention to Note 5 to the consolidated financial results which describes the litigations and issues pertaining to regularization of the hospital building in which the Parent Company operates as at 31 December 2023 and the subsequent Business Transfer Arrangement (“BTA”) entered into by the Parent Company and related matters.

Subsequent to entering into the BTA, the Parent Company is no longer associated with the hospital building and related uncertainties such as pending regularization and ongoing litigations related thereto.

Further, post the BTA the Parent Company ceases to have any business operations and will evaluate in due course the utilization of its resources. However, the Parent Company believes that it has sufficient cash and cash equivalent to settle its obligations as and when they fall due, and it believes

Registered Office:

Limited Review Report (Continued)

Fortis Malar Hospitals Limited

that it would be able to meet its financial requirements and have accordingly prepared the financial results on a going concern basis.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

**HARSH VARDHAN
LAKHOTIA**

Digitally signed by HARSH

VARDHAN LAKHOTIA

Date: 2024.02.05 17:49:29

+05'30'

Harsh Vardhan Lakhotia

Partner

Membership No.: 222432

UDIN:24222432BKGUDA7286

Chennai

05 February 2024